The Serum Institute of India & Department of Biotechnology are set to launch the country's first indigenously developed Quadrivalent Human Papillomavirus vaccine against cervical cancer.
Pune-based SII has got the go-ahead from the Drugs Controller General of India to market the vaccine. Cervical cancer is one of the leading causes of female cancer mortality worldwide.
Cervical cancer in India is the 2nd most frequent cancer among women between 15-44 years of age. Currently, India is fully dependent on foreign manufacturers for the vaccine.
The SII will commence Covid vaccine export under the COVAX programme from 23 November. Nepal, Tajikistan, Mozambique and Bangladesh are the 4 nations that will receive the doses.
SII's Director of Government and Regulatory Affairs is learnt to have recently communicated to Union Health Ministry that it has a manufactured stock of 24,89,15,000 Covishield doses.
Serum Institute of India, world's largest vaccine manufacturer, will market the nanoparticle protein-based vaccine in Indonesia under the brand name Covovax.
Under the deal, Biocon Biologics Ltd (BBL) will offer approximately 15% stake to Serum Institute Life Sciences at a post-money valuation of about Rs 35,000 crore.
New Delhi, Nov 16 (PTI) The National Financial Reporting Authority (NFRA) will carry out audit quality inspections of five audit firms, including the...
No matter what tactics, doctrine, or weapon system is used, the objective of any war is to control territory, argues Gen. MM Naravane (retd). But it's politics that matters most.